AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8⁺ T cell immunity

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Interferon-gamma (IFN-γ) is vital for anti-tumor immunity and immunotherapy success.
• Argonaute 2 (AGO2) regulates gene expression via small RNAs.
• Tumor resistance to IFN-γ and immunotherapy remains a clinical challenge.

Purpose of the Study:

• To investigate the role of AGO2 in tumor response to IFN-γ and immunotherapy.
• To elucidate the molecular mechanism by which AGO2 affects IFN-γ signaling.
• To evaluate therapeutic strategies targeting the AGO2-miR-1246 axis.

Main Methods:

• Correlation analysis of AGO2 expression with tumor responsiveness.
• Mechanistic studies involving miR-1246, AGO2, STAT1, and PTPN6.
• Preclinical cancer models treated with AGO2 inhibitor (BCI-137) or miR-1246 antagomir.
• Assessment of immune cell infiltration, activation, and cytotoxicity.

Main Results:

• AGO2 expression inversely correlates with tumor responsiveness to IFN-γ and immunotherapy.
• IFN-γ upregulates miR-1246, which complexes with AGO2 to stabilize PTPN6 mRNA.
• This complex inhibits STAT1 phosphorylation, reducing CXCLs, ISGs, and HLA expression, promoting immune evasion.
• Inhibition of AGO2 or miR-1246 restored IFN-γ sensitivity and enhanced anti-tumor CD8+ T cell responses.

Conclusions:

• AGO2 and miR-1246 mediate resistance to IFN-γ and immunotherapy by suppressing key immune signaling pathways.
• Targeting the AGO2-miR-1246 interaction represents a promising strategy to overcome immunotherapy resistance.
• Restoring IFN-γ responsiveness through AGO2 or miR-1246 inhibition enhances anti-tumor immunity and treatment efficacy.